Clearmind Advances AUD Trial After DSMB Greenlight — Clearmind Medicine Inc.

Event summary

Clearmind's Phase I/II trial for CMND-100 in AUD patients advances to Parts B and C after DSMB approval.
Part B will evaluate CMND-100 in moderate-to-severe AUD patients, while Part C continues safety assessments in healthy participants.
The trial is being conducted at leading clinical sites including Johns Hopkins University and Yale School of Medicine.
CMND-100 demonstrated favorable safety and tolerability in Part A of the study.

The big picture

Clearmind's advancement in its AUD trial reflects growing interest in neuroplastogen-derived treatments that avoid the perceptual effects of classical psychedelics. The company's focus on scalable, non-hallucinogenic solutions aligns with broader industry trends toward more accessible mental health interventions. Success in this trial could position Clearmind as a key player in the emerging neuroplasticity-focused treatment space.

What we're watching

Clinical Efficacy: How CMND-100's potential to reduce alcohol consumption and craving will be demonstrated in Part B.
Regulatory Pathway: Whether the non-hallucinogenic profile of CMND-100 will facilitate faster regulatory approvals.
Market Differentiation: The pace at which Clearmind can position CMND-100 as a scalable treatment alternative to existing AUD therapies.